Skip to main content
Clinical Trials/CTRI/2014/09/005045
CTRI/2014/09/005045
Completed
Phase 4

Comparison of bronchodilator responses of single dose of Tiotropium and Formoterol with 4 doses of Ipratopium and Salbutamol administered via dry powder inhaler, over a period of 24 hours, in adult subjects with COPD.

Cipla Ltd0 sites18 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Subjects diagnosed with COPD according to Global Initiative of Obstructive Lung Disease (GOLD) guidelines
Sponsor
Cipla Ltd
Enrollment
18
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
Cipla Ltd

Eligibility Criteria

Inclusion Criteria

  • COPD diagnosed according to GOLD criteria (Appendix 1\)
  • Airway reversibility â?? increase of at least of 12% of FEV1 from the baseline 30 minutes post inhaled 40 mcg of Ipratropium bromide and 200 mcg of Salbutamol combination both delivered through a rotahaler.
  • FEV1 less than 65%of the predicted normal and FEV1 /FVC \< 70%
  • Male or female subjects between 40 to 70years of age
  • No COPD exacerbation during past one month
  • Smoking history \> 10 pack years or significant occupational history
  • Written informed consent

Exclusion Criteria

  • Exacerbation as judged by the investigator within 4 week prior to screening
  • Unable to discontinue long\-acting bronchodilators including theophylline for 24 hours and short acting bronchodilators for 6 hours prior to onset on the study day.
  • Radiological or clinical evidence of other pulmonary diseases
  • Subjects with the clinical evidence of heart failure or arrhythmias.
  • Concurrent diseases likely to affect the study e.g. tuberculosis, bronchogenic carcinoma, pneumonia, ischemic heart disease, liver disease etc.
  • Subjects unable to perform lung functions
  • Participation in other clinical studies during the month prior to visit 1
  • Subject too ill as judged by the investigators to participate.
  • Subject with history of asthma or hay fever or blood eosinophil count over 400mm3 will be Excluded
  • Pregnant and lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials